EGA
SKBI

Eagle Global Advisors’s SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) SKBI Stock Holding History

Eagle Global Advisors’s Portfolio SKBI Stock Details SKBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-11,288
Closed -$30K – 420
2015
Q2 		$30K Sell
11,288
-11,288
-50% -$38.6K ﹤0.01% 383
2015
Q1 		$88K Hold
22,576
– – ﹤0.01% 347
2014
Q4 		$95K Hold
22,576
– – ﹤0.01% 327
2014
Q3 		$95K Buy
22,576
+2,380
+12% +$12.9K ﹤0.01% 323
2014
Q2 		$148K Buy
+20,196
New +$120K ﹤0.01% 313

Other funds holding SKBI

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Eagle Global Advisors's SKBI Position: Q3 2015 in Review

Eagle Global Advisors sold out of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) in Q3 2015, closing a stake of 11,288 shares — an estimated $30K sold.

Eagle Global Advisors first reported a position in SKBI in Q2 2014 and held it in 5 quarters. The position peaked at $148K in Q2 2014. 10 funds tracked by Wall St. Rank hold SKBI as of Q3 2015.

  • Eagle Global Advisors reported no remaining SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position as of Q3 2015 after selling out during the quarter.
  • Eagle Global Advisors sold 11,288 SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) shares in Q3 2015, an estimated $30K.
  • Eagle Global Advisors first reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in Q2 2014 and held it in 5 quarters.
  • Eagle Global Advisors's SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position peaked at $148K in Q2 2014.
  • 10 funds tracked by Wall St. Rank held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) as of Q3 2015.

Based on Eagle Global Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.